Tag Archives: biotechnology

Ignorance is Bliss – for Teva

Posted on August 4, 2014 by Warren Woessner

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading →

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment

USPTO TRIPs over Myriad-Mayo guidance

Posted on July 31, 2014 by Warren Woessner

Timothy W. Roberts, Chartered Patent Attorney; MA (Oxon); LL.D (honoris causa, Sheffield University) Paul G. Cole,  Chartered Patent Attorney;  MA (Oxon); LLM, NottinghamTrent; Visiting Professor, Bournemouth University The above UK-based European Practitioners have today filed comments at the USPTO arguing … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment

Abbvie V. Janssen Biotech –Written Description Requirement Road Map

Posted on July 7, 2014 by Warren Woessner

The recent decision in Abbvie Deutschland v. Janssen Biotech and Centorcor Biologics, App. No. 2013-1338, -1346 (Fed. Cir. , July 1, 2014) deserves more attention than it has received. (A copy of the decision is available at the end of … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | 1 Comment